Rentschler Biotechnologie, a Laupheim, Germany-headquartered contract development and manufacturing organization (CDMO) for biopharmaceuticals, has formed a strategic alliance with Leukocare, a Martinsried, Germany-headquartered drug formulation company focused on protein therapeutics, under which Leukocare will become the specialized technology partner and the exclusive formulation developer for Rentschler’s biopharmaceuticals business. Rentschler in return will have access to Leukocare´s patented stabilizing and protecting solutions (SPS) formulation technologies.

Under the agreement, Rentschler will acquire a 10% stake in Leukocare and Dr. Frank Mathias, chief executive officer of Rentschler, will join Leukocare’s board of directors.

Leukocare provides formulation development services based on its proprietary SPS technology platform, which is designed to improve the stability of therapeutic proteins by, for example, giving stability at higher temperatures and providing longer shelf life. The SPS technology platform is characterized by specific combinations of excipients.

Source: Rentschler Biotechnologie